AKT1 and liver cancer: In liver cancer, salvigenin was reported to have the ability to reduce the proliferation, migration and invasion of hepatocellular HCC cells and suppress cell glycosides and chemoresistance by modulating the PI3K/AKT/GSK-3β pathway [193].